How to Become a STELFONTA® (tigilanol tiglate injection) SUPERSTAR: Part 4 of 4

1.0 CE Credit Hour / Veterinarians & Veterinary Technicians

Overview:

The final session of the four-part series brings everything together so that participants are fully confident in treating their next suitable case. We will focus on the suitability of STELFONTA® for various anatomic locations and how to step-up its application to treat more complex cases. We also share the experiences of pet owners caring for their dog through the journey. Additionally, we will introduce the STELFONTA® community, including a Facebook group for veterinary professionals, meet-ups at conferences, and Zoom sessions with Dr. Sue.

Learning Objectives:

  • Briefly summarize the key points covered in the STELFONTA® webinar series to date. 
  • Discuss the suitability of STELFONTA® for various anatomic locations and strategies to step-up its application. 
  • Share experiences from pet owners to illustrate the treatment's real-world impact and preference. .
  • Introduce the STELFONTA® community, including a dedicated Facebook group for veterinary professionals, meet-ups at major conferences, and Zoom sessions with Dr. Sue.
  • Provide participants with resources and connections to continue their learning and engagement with STELFONTA®.

IMPORTANT SAFETY INFORMATION
Accidental self-injection of STELFONTA® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit https://vet-us.virbac.com/stelfonta.

    Dr Sue Ettinger

    Dr Sue Ettinger

    DVM, Diplomate ACVIM (Oncology)

    This course is RACE-approved for 1.0 continuing education credits hours in jurisdictions that accept RACE-approval.

    This activity is sponsored by Virbac.